Market Cap
$106,164,520,358
Enterprise Value
$140,194,520,358
Average Volume
$16,324,425
BRISTOL MYERS SQUIBB CO - BMY
$52.15
+0.20
(0.38%)
Valuation & Solvency
P/Tangible Book
5.73
P/E
17.60
P/S
2.21
EV/EBITDA
9.72
EV/Sales
2.92
EV/FCF
9.16
Dividend Yield
4.76%
Payout Ratio
82.81%
Total Debt
$49,192,000,000
Cash & Marketable Securities
$16,502,000,000
Quick Ratio
1.17
Debt/Equity
2.75
Net Debt/EBITDA
2.36
Interest Coverage Ratio
7.06
About
Industry
Drug Manufacturers - General
Exchange
NYSE
Country
US
Beta
0.30
Company Description
▶
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.